Tevogen Bio Holdings (TVGN) AI Stock Analysis

• Market Cap: $190.81M
• Dividend Yield: N/A
• Average Volume (3M): 509.22K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.62
• Revenue Growth: N/A
• EPS Growth: -177.18%
• Country: US
• Employees: 17
• Sector: Financial
• Sector Strength: 84
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 175,051,250
• 10 Day Avg. Volume: 305,596
• 30 Day Avg. Volume: 509,221
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -13.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.00
• Price Target Upside: 834.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Tevogen Bio Holdings has a low overall stock score, primarily due to severe financial challenges, including significant operational losses and negative equity. Despite positive short-term technical trends and recent funding that could support strategic initiatives, the company's financial instability and valuation issues remain major concerns impacting the score negatively.

Tevogen Bio Holdings Business Overview & Revenue Model

Company Description

Tevogen Bio Holdings (TVGN) is a biotechnology company focused on developing innovative therapies for infectious diseases and cancers. The company leverages advanced cellular and genetic engineering technologies to create targeted treatments, with a particular focus on T cell and immunotherapy-based solutions. Tevogen Bio aims to address unmet medical needs by providing effective and scalable therapeutics that improve patient outcomes.

How the Company Makes Money

Tevogen Bio Holdings generates revenue primarily through the development and commercialization of its proprietary therapies. The company's revenue model includes partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare providers for the co-development and distribution of its products. Additionally, Tevogen may engage in licensing agreements, providing its technology to other entities in exchange for upfront payments, milestone payments, and royalties based on sales. The company's earnings are significantly influenced by its ability to successfully navigate clinical trials, obtain regulatory approvals, and achieve market penetration for its therapies.

Tevogen Bio Holdings Financial Statement Overview

Summary

Tevogen Bio Holdings is facing significant financial difficulties across all aspects of its financial statements. The absence of revenue, coupled with negative profitability and cash flow metrics, highlights severe operational and financial challenges. Negative equity and cash flow issues indicate high financial risk, requiring immediate strategic intervention to improve its fiscal stability.

Income Statement

Tevogen Bio Holdings has reported no revenue, leading to negative gross profit, EBIT, and net income figures, indicating operational challenges. The lack of revenue growth and consistent losses highlight significant profitability issues and raise concerns about the company's ability to generate sales.

Balance Sheet

The balance sheet shows negative stockholders' equity, which is a critical risk indicating that liabilities exceed assets. High total debt and negative equity ratios suggest financial instability and potentially high leverage, further raising concerns about the company's financial health.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating cash outflows from operations. The company's reliance on external financing is evident, but the negative free cash flow to net income ratio signals a lack of cash generation, exacerbating liquidity concerns.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
-198.29K	0.00	0.00	0.00
	EBIT
-44.85M	―	-13.72M	-4.62M
	EBITDA
-3.31M	188.71K	-953.08K	-28.75K
	Net Income Common Stockholders
-5.11M	-67.33K	4.41M	-15.60M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
344.58K	8.84K	129.19K	7.12M
	Total Assets
352.85M	17.04M	357.14M	7.66M
	Total Debt
0.00	1.63M	40.01M	23.48M
	Net Debt
-344.58K	1.62M	39.88M	16.36M
	Total Liabilities
15.18M	17.73M	15.06M	24.15M
	Stockholders Equity
337.67M	-695.80K	342.08M	-16.49M
Cash Flow		Free Cash Flow
-9.64M	-1.38M	-694.44K	-5.38M
	Operating Cash Flow
-9.64M	-1.38M	-215.40K	-5.27M
	Investing Cash Flow
9.65M	342.92M	―	-109.73K
	Financing Cash Flow
938.05K	-341.66M	7.50K	12.50M

Tevogen Bio Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVGN, the sentiment is Negative. The current price of 1.07 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.31, and above the 200-day MA of 1.05, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 40.89 is Neutral, neither overbought nor oversold. The STOCH value of 21.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TVGN.

Tevogen Bio Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$14.39B	9.81	8.95%	4.37%	16.38%	-11.64%
BNTX	54 Neutral	$21.67B	―	-3.38%	―	-27.64%	-172.62%
BCRX	52 Neutral	$1.51B	―	18.68%	―	36.00%	63.50%
VIR	51 Neutral	$847.55M	―	-38.09%	―	-13.90%	16.56%
MRNA	48 Neutral	$10.48B	―	-28.77%	―	-52.75%	25.00%
TVGN	40 Underperform	$190.81M	―	-124.74%	―	―	-177.18%
NVAX	39 Underperform	$965.07M	―	30.06%	―	-30.65%	77.62%

Tevogen Bio Holdings Corporate Events

Tevogen Bio Holdings Secures Funding for Therapeutics and AI

On January 28, 2025, Tevogen Bio Holdings Inc. announced it received an initial $2 million grant from KRHP LLC, with the potential for an additional $8 million in non-dilutive funding, to support the development of T cell therapeutics for cancers and viral infections. The grant will also aid in expanding the company’s artificial intelligence efforts, Tevogen.AI, and comes alongside a previously announced $36 million loan agreement, reflecting the company’s strategic focus on efficient operations and innovation.